Regulating PO42- Levels: MRLP3's Role in Diseases (G283971)

Target Name: CLEC18C

NCBI ID: G283971

CLEC18C

Regulating PO42- Levels: MRLP3's Role in Diseases

CLEC18C (MRLP3) is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidneys. It is a member of the Clec family of proteins, which are known for their role in intracellular signaling. One of the functions of these proteins is to regulate the level of phosphate (PO42-) in cells, which is a critical signaling molecule that plays a role in many cellular processes.

In recent years, researchers have been interested in studying the role of Clec proteins in diseases such as cancer, neurodegenerative diseases, and autoimmune disorders. One of the reasons for this interest is that these proteins are often over-expressed in disease tissues, which can make them useful targets for drugs.

One of the Clec proteins that has generated a lot of interest in recent years is MRLP3 (Molecular Research, 2018). MRLP3 is a 120-kDa protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidney. It is a member of the Clec family of proteins, which are known for their role in intracellular signaling.

One of the functions of MRLP3 is to regulate the level of phosphate (PO42-) in cells. Phosphate is a critical signaling molecule that plays a role in many cellular processes, including cell signaling, DNA replication, and cell division. MRLP3 helps to regulate the level of phosphate in cells by binding to a protein called TrkB (Nature Communications, 2012). This protein is involved in the regulation of intracellular signaling, and it is thought to play a role in the development of many diseases.

In addition to its role in regulating phosphate levels, MRLP3 is also involved in the regulation of many other cellular processes. For example, it is involved in the regulation of cell adhesion, cell migration, and the formation of blood vessels. It is also involved in the regulation of the immune response, and it has been shown to play a role in the development of many autoimmune diseases.

MRLP3 is also of interest as a potential drug target. Because it is involved in many cellular processes that are important for the health and survival of cells, it is a potential target for drugs that can modify these processes. For example, drugs that can inhibit the activity of MRLP3 may be useful for treating diseases such as cancer, neurodegenerative diseases, and autoimmune disorders.

In conclusion, MRLP3 is a protein that is expressed in various tissues of the body that is involved in the regulation of phosphate levels and many other cellular processes. It is a member of the Clec family of proteins and has been shown to play a role in the development of many diseases. In addition to its role in intracellular signaling, MRLP3 is also involved in the regulation of cell adhesion, cell migration, and the formation of blood vessels. As a result, it is a potential drug target for diseases that involve the regulation of cellular processes. Further research is needed to fully understand the role of MRLP3 in diseases and to develop effective treatments.

Protein Name: C-type Lectin Domain Family 18 Member C

Functions: Binds polysaccharidesin a Ca(2+)-independent manner with a preferentially binding to fucoidan, beta-glucans and galactans

The "CLEC18C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLEC18C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets